logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
F

Frédèric Selle

oncology department
H指数:40
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial.

转移性子宫内膜癌患者中分子分型与总生存期的关联：UTOLA II期GINECO试验的辅助结果。

International Journal of Gynecological Cancer
IF4.7
2025-11-210
PRE
Guillaume Beinse; Karen Leroy; Pierre-Alexandre Just; Corinne Jeanne; François Cherifi; Alexandra Leary; Olivia Le Saux; Benoît You; Manuel Rodrigues; Laurence Gladieff; Sophie Abadie-Lacourtoisie; Leïla Bengrine Lefevre; Pierre-Emmanuel Brachet; Coriolan Lebreton; Guillaume Meynard; Pierre Fournel; Jean-Sébastien Frenel; Frédéric Selle; Rémy Largillier; Cyril Foa
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial

奥拉帕利维持治疗在铂类为基础化疗后的晚期/转移性子宫内膜癌中的应用：GINECO随机IIb期UTOLA试验

Nature Communications
IF15.7
2025-08-260
OAAI
Florence Joly; Alexandra Leary; Isabelle Ray-Coquard; Bernard Asselain; Manuel Rodrigues; Laurence Gladieff; Guillaume Meynard; Sophie Abadie-Lacourtoisie; Coriolan Lebreton; Leïla Bengrine Lefevre; Pierre Fournel; Rémy Largillier; Frédéric Selle; Jean-Sébastian Frenel; Yolanda Fernandez Diez; Cyril Foa; Philippe Follana; Jérôme Meunier; Michel Fabbro; Anne-Claire Hardy Bessard; Isabelle Cojean-Zelek; Emilie Kaczmarek; Elise Bonnet; Antoine Arnaud; Sophie Roche; Karen Leroy; Pierre-Alexandre Just; Raphaël Leman; Corinne Jeanne; Céline Callens; Benoit You; Jérôme Alexandre
Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study

复发卵巢癌患者中结合肿瘤大小动态和CA-125动力学的一种联合K-PD模型的预后价值：BOLD二期GINECO研究

cpt pharmacometrics systems pharmacology
IF0
2025-07-070
OA
Aurore Carrot; Pauline Corbaux; Olivier Colomban; Coriolan Lebreton; Laurence Gladieff; Olivier Tredan; Frédéric Selle; Cyril Abdeddaim; Alexandra Leary
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer

NSGO-FANDANGO/ENGOT-EN1：一项关于在晚期/复发性子宫内膜癌中使用尼达尼布/安慰剂联合一线化疗的随机Ⅱ期研究

gynecologic oncology
IF4.1
2025-06-300
PRE
Kristina Lindemann; Dominique Berton; Jalid Sehouli; René DePont Christensen; Sevilay Altintas; Anja Ør Knudsen; Pierre-Etienne Heudel; Beyhan Ataseven; Ignace Vergote; Gabriel Lindahl; Coriolan Lebreton; Fabienne Schochter; Annika Auranen; Philippe Follana; Kristine Madsen; Frédéric Selle; Karen Stampe Petersson; Florence Joly; Elena Ioana Braicu; Mansoor Raza Mirza
Ovarian Clear Cell Carcinoma: Prognostic And Predictive Factors. A Multicenter Retrospective Study

卵巢透明细胞癌：预后与预测因素。一项多中心回顾性研究

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
IF4.7
2025-02-010
PRE
Rosso, Roberta; Turinetto, Margherita; Treilleux, Isabelle; Ouldbey, Yaelle; Penault-Llorca, Frederique; Genestie, Catherine; Croce, Sabrina; Devouassoux, Mojgan; Henno, Sebastien; Lefeuvre, Claudia; Vincent-Salomon, Anne; Charafe-Jauffret, Emmanuelle; Provensal, Magali; Belda, Marie-Aude Le Frere; Selle, Frederic; Meeus, Pierre; Chopin, Nicolas; Le Saux, Olivia; Ferraioli, Domenico; Ray-Coquard, Isabelle
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
JNCI CANCER SPECTRUM
IF4.1
2024-12-141
OAAI
Joly, Florence; Bazan, Fernando; Garbay, Delphine; Ouldbey, Yaelle; Follana, Philippe; Champeaux-Orange, Elise; Legouffe, Eric; Brachet, Pierre-Emmanuel; Spaeth, Dominique; Combe, Pierre; Hardy-Bessard, Anne-Claire; Selle, Frederic; Grenier, Julien; Lebreton, Coriolan; Derbel, Olfa; Bonnet, Elise; Fournel, Pierre; Diez, Yolanda Fernandez; Delecroix, Valerie; Emambux, Sheik; Alexandre, Jerome; Grellety, Thomas; Mille, Dominique; Orfeuvre, Hubert; Favier, Catherine; Le Roux, Delphine; Mouret-Reynier, Marie-Ange; Quesada, Stanislas; Kurtz, Jean-Emmanuel
Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA

循环肿瘤DNA在转移性子宫内膜癌预后判断和监测中的验证：GINECO试验UTOLA II期随机研究的附加结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Beinse, G.; Taly, V.; Leary, A.; Baures, A.; Tredan, O.; You, B.; Rodrigues, M. J.; Gladieff, L.; Lacourtoisie, S. Abadie; Lefevre, L. Bengrine; Brachet, P-E.; Lebreton, C.; Kalbacher, E.; Fournel, P.; Frenel, J-S.; Selle, F.; Largillier, R.; Laurent-Puig, P.; Lobbedez, F. Joly; Alexandre, J.
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
NATURE COMMUNICATIONS
IF15.7
2024-07-162
OAAI
Ray-Coquard, Isabelle L.; Savoye, Aude-Marie; Schiffler, Camille; Mouret-Reynier, Marie-Ange; Derbel, Olfa; Kalbacher, Elsa; Leheurteur, Marianne; Martinez, Alejandra; Cornila, Corina; Martinez, Mathilde; Bengrine Lefevre, Leila; Priou, Frank; Cloarec, Nicolas; Venat, Laurence; Selle, Frederic; Berton, Dominique; Collard, Olivier; Coquan, Elodie; Le Saux, Olivia; Treilleux, Isabelle; Gouerant, Sophie; Angelergues, Antoine; Joly, Florence; Tredan, Olivier
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial

先前接受PARP抑制剂 (OReO/ ENGOT-ov38) 治疗的铂敏感复发性卵巢癌患者的维持olaparib再激发: IIIb期试验

ANNALS OF ONCOLOGY
IF65.4
2023-12-0123
OA
Pujade-Lauraine, E.; Selle, F.; Scambia, G.; Asselain, B.; Marme, F.; Lindemann, K.; Colombo, N.; Madryl, R.; Glasspool, R.; Vergote, I.; Korach, J.; Lheureux, S.; Dubot, C.; Oaknin, A.; Zamagni, C.; Heitz, F.; Gladieff, L.; Rubio-Perez, M. J.; Scollo, P.; Blakeley, C.; Shaw, B.; Ray-Coquard, I; Redondo, A.
Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
ANNALS OF ONCOLOGY
IF65.4
2023-10-012
PRE
Martin, A. Gonzalez; Perez, M. J. Rubio; Heitz, F.; Christensen, R. D.; Colombo, N.; Van Gorp, T.; Oaknin, A.; Leary, A.; Garcia, L. Gaba; Lebreton, C.; Gonzalez, L. M. De Sande; Marin, M. Romeo; Redondo, A.; Ginesta, M. P. Barretina; Fidalgo, J. A. Perez; Bertran, A. Santaballa; Bermejo-Perez, M. J.; Bruchim, I.; Ray-Coquard, I. L.; Selle, F.
First results from the ENGOT-GYN2/ GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) plus bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)
ANNALS OF ONCOLOGY
IF65.4
2023-10-014
OA
Ray-Coquard, I. L.; Pignata, S.; Lee, J-Y.; Coleman, R. L.; Brown, J.; Kim, J-W.; Selle, F.; Lorusso, D.; Bermejo-Perez, M. J.; Pautier, P.; Gourley, C.; Ayhan, A.; Richardson, G.; Cibula, D.; Yauch, L.; Dieterich, M.; Krishnan, V.; Calas-Zeroug, O.; Harter, P.; Gershenson, D. M.
Olaparib vs placebo as maintenance therapy after platinumbased chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
ANNALS OF ONCOLOGY
IF65.4
2023-10-014
OA
Lobbedez, F. Joly; Leary, A.; Ray-Coquard, I. L.; Asselain, B.; Rodrigues, M. J.; Gladieff, L.; Bazan, F.; Lacourtoisie, S. Abadie; Lebreton, C.; Lefevre, L. Bengrine; Leroy, K.; Leman, R.; Fournel, P.; Largillier, R.; Selle, F.; Frenel, J-S.; Fernandez, Y.; Foa, C.; You, B.; Alexandre, J.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

奥拉帕利联合贝伐单抗一线维持治疗卵巢癌: PAOLA-1/ENGOT-ov25试验的最终总生存期结果

ANNALS OF ONCOLOGY
IF65.4
2023-08-0181
OA
Ray-Coquard, I.; Leary, A.; Pignata, S.; Cropet, C.; Gonzalez-Martin, A.; Marth, C.; Nagao, S.; Vergote, I.; Colombo, N.; Maenpaa, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Alia, E. M. Guerra; Bogner, G.; Yoshida, H.; Lefeuvre-Plesse, C.; Buderath, P.; Mosconi, A. M.; Lortholary, A.; Burges, A.; Medioni, J.; El-Balat, A.; Rodrigues, M.; Park-Simon, T. -W.; Dubot, C.; Denschlag, D.; You, B.; Pujade-Lauraine, E.; Harter, P.
Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
ANNALS OF ONCOLOGY
IF65.4
2022-09-0132
OA
Ray-Coquard, I. L.; Leary, A.; Pignata, S.; Cropet, C.; Gonzalez Martin, A. J.; Bogner, G.; Yoshida, H.; Vergote, I. B.; Colombo, N.; Maenpaa, J.; Selle, F.; Schmalfeldt, B.; Scambia, G.; Guerra Alia, E. M.; Lefeuvre-Plesse, C.; Belau, A.; Lortholary, A.; Gropp-Meier, M.; Pujade-Lauraine, E.; Harter, P.
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
BRITISH JOURNAL OF CANCER
IF6.8
2022-03-3112
OA
You, Benoit; Van Wagensveld, Lilian; Tod, Michel; Sonke, Gabe S.; Horlings, Hugo M.; Kruitwagen, R. F. P. M.; Du Bois, Andreas; Selle, Frederic; Perren, Timothy; Pfisterer, Jacobus; Joly, Florence; Cook, Adrian; Kaminsky, Marie Christine; Wollschlaeger, Kerstin; Lortholary, Alain; Tome, Oliver; Leary, Alexandra; Freyer, Gilles; Van der Aa, Maaike; Colomban, Olivier

研究方向

暂未获取到该数据
A
Alexandra Léary
H 指数:62论文数:715被引数:2.4万
A
Anne Floquet
H 指数:52论文数:496被引数:1.8万
L
Laurence Gladieff
H 指数:43论文数:347被引数:9,730
É
Éric Pujade-Lauraine
H 指数:69论文数:608被引数:2.6万
B
Benoît You
H 指数:47论文数:547被引数:1.1万
J
Jérôme Alexandre
H 指数:29论文数:269被引数:3,705
A
Alain Lortholary
H 指数:51论文数:382被引数:1.8万
F
Florence Joly
H 指数:73论文数:648被引数:2.3万
C
Coriolan Lebreton
H 指数:3论文数:8被引数:39
M
Michel Fabbro
H 指数:52论文数:422被引数:1.1万